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Background: Body habitus differences may explain some of the variation in lung function between individuals with cystic ﬁbrosis (CF). We tested
the hypothesis that measures of lean muscle mass and obesity are independently associated with lung function in CF.
Methods: Cross-sectional study design using UK CF registry data from 2096 clinically stable adults.
Results: Serum creatinine and BMI were positively and independently associated with FEV1 and FVC. One standard deviation increment in serum
creatinine was associated with an FEV1 increase of 171 ml (95% conﬁdence intervals CI: +116 to +227 ml) in males and 90 ml (95% CI: +46 to
+133 ml) in females. Compared to the reference group of 20–24.9 kg/m2, those with a BMIb20 kg/m2 had lower FEV1 with values of −642 ml
(95%CI: −784 to −500 ml) for males and −468 ml (95%CI: −564 to −372 ml) for females.
Conclusions: Prospective studies and controlled trials are required to ascertain if these associations have therapeutic potential in modifying disease
progression.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Body mass index; Lung function; Muscle; Cystic ﬁbrosis1. Introduction
Cystic fibrosis (CF) is the most commonly inherited fatal
disease in the Caucasian population. Characteristic features of
the disease include recurrent pulmonary infections and malab-
sorption which contribute to accelerated loss of lung function and
weight [2], and are associated with higher levels of mortality [3].
Hence, lung function and nutritional status are important clinical
outcome measures that predict morbidity and mortality [4,5] and
as a consequence are used to monitor the clinical condition of☆ Data originally presented at NACF Conference in Anaheim, California,
USA in 2011 [1].
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http://dx.doi.org/10.1016/j.jcf.2012.08.008individuals with a diagnosis of CF. The most accessible measure
of nutritional status is body mass index (BMI), and this is
routinely recorded as part of the clinical data collection for CF.
There have been a number of smaller cross-sectional stud-
ies demonstrating that lung function as measured by Forced
Expiratory Volume in one second (FEV1) is positively associated
with BMI, consistent with the hypothesis that both are measures
of disease severity [6–11]. Data from the CF Foundation Registry
has consistently demonstrated that this inverse association be-
tween BMI and lung function is also present in population-based
epidemiological data [12–14], and a study from the European
Epidemiologic Registry of Cystic Fibrosis demonstrated lower
function in those with decreased weight for height percentiles
[15]. More recently, there have been a number of studies
exploring the association between lean muscle mass (a differentby Elsevier B.V. All rights reserved.
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[16–20]. Similarly to the earlier studies of BMI, the numbers
studied are relatively small and it is unclear if these associations
are present in larger, nationally representative populations.
Creatinine is released by skeletal muscle at a constant rate
proportionate to total muscle mass and provides an epidemio-
logical biomarker of total body skeletal muscle [21–23], with
serum creatinine being strongly associated (r=0.73) with fat-free
mass [24]. We have recently demonstrated that serum creatinine
is inversely associated with mortality in adult patients with cystic
fibrosis [25]. Using the national UK database for CF, we tested
the hypothesis that two measures of body habitus, serum
creatinine and BMI, are positively associated with lung function
in clinically stable adults with a diagnosis of CF. We quantified
the relative contributions of these two exposures adjusting for
potential confounding factors. Some of the results of these studies
have previously been published in the form of an abstract.
2. Materials and methods
2.1. Study population and data collection
The study population consisted of individuals registered on
the UK Cystic Fibrosis Registry aged 18 years or over who
attended for an annual assessment visit in 2008 and were
considered to be clinically stable by their physician. The registry
is administered by the UK Cystic Fibrosis Trust and records
information about the health and treatment of patients annually.
Data are collected from 50 British CF care centres in a stan-
dardised anonymous fashion after obtaining patient consent.
Each patient has an annual assessment visit when, among other
investigations, lung function, weight, height and serum creatinine
levels are measured and their clinical status is classified as stable
or not. The main exposures of interest were serum creatinine,
height and body mass index. The main outcome measure of
interest was lung function as measured by forced expiratory
volume in one second (FEV1) and forced vital capacity (FVC).
2.2. Statistical analysis
The data were visually examined for outlying values and any
implausible values removed along with any values of creatinine
greater than 300 μmol/L. The age was calculated for each
individual on the 1st January 2008. The association between
BMI and serum creatinine and FEV1 and FVC were explored
using linear regression using quintiles of serum creatinine and
BMI (coded as a categorical variable with the categories
b20 kg/m2, 20–24.9 kg/m2, N25 kg/m2) adjusting for sex, age
(coded as a categorical variable, b20, 20–29, 30–39, 40+
years) and height as a priori confounding factors. The addition
of height squared did not modify the size of associations by
more than 10% and this was omitted from the final model.
Likelihood ratio testing was used to test the linearity of these
associations, and as the relation for serum creatinine and FEV1
was linear these data for this association was presented per
standard deviation increment. The association between BMI
and FEV1 was non-linear (p=0.01) and hence this was presentedas a categorical variable. The association between creatinine and
FEV1 was modified by gender (LRT for interaction, p=0.03),
and the data were presented stratified for sex. Sensitivity anal-
yses were used to explore the consistency of the associa-
tions observed, using different cut off points for creatinine of
150 μmol/L and 100 μmol/L to ensure that they were not being
driven by extreme values. All analyses were performed using
STATA SE 11.0 (Stata Corporation, Texas) statistical software.
3. Results
2096 (56% male) patients attended for annual assessment in
2008 and provided complete data for analysis (Fig. 1). The clinical
and physical status of those providing both FEV1 and serum
creatinine data was not significantly different from those who did
not (Table 1). For those who provided complete data, mean
creatinine for males was 84.0 μmol/L (standard deviation[sd]
20.2 μmol/L) and for females was 68.6 μmol/L (sd 21.1 μmol/L).
The basic data of the association between predicted FEV1 and BMI
is presented in Fig. 2.
In the final multivariate model both serum creatinine and
BMI were positively associated with FEV1 and FVC after
mutual adjustment. After stratification for gender, a single
standard deviation change in serum creatinine was associated
with changes in FEV1 +171 ml (95% confidence intervals[CI}:
+116 ml to +227 ml) for males and +90 ml (95%CI: +46 ml
to +133 ml) in females respectively with similar changes seen
in FVC (Table 2). The size of these associations was larger after
using cuff off points of 100 μmol/L and 150 μmol/L as the
highest level of creatinine values in the sensitivity analyses.
Hence, the more conservative results are presented.
Modelled as a categorical variable using 20–24.9 kg/m2 as a
reference group, BMI was strongly associated with lung
function (Table 2). In males, those with a BMI of less than
20 kg/m2 had a FEV1 −642 ml (95%CI: −784 ml to −500 ml)
lower than the reference group, while those with a BMI greater
or equal to 25 kg/m2 had a FEV1 +364 ml (95%CI: +227 ml
to +501 ml) greater than the reference group. Similar results
were seen in for FVC and also in the analysis stratified for
female sex.
4. Discussion
We have used national data from the United Kingdom
Cystic Fibrosis Registry to demonstrate for the first time a
positive linear association between an epidemiological measure
of lean muscle mass (serum creatinine) and two measures of
lung function, FEV1 and FVC. This is consistent with our
hypothesis that total skeletal muscle mass is positively associated
with lung function in this population. We have also confirmed
and quantified the previously reported positive association
between obesity as measured by BMI and lung function in a
large epidemiological study population, having adjusted for the
impact of muscle mass.
The strength of these data is the large, nationally representa-
tive nature of the UK national CF registry[26], that permits
cross-sectional studies to be undertaken in the knowledge that
Study population
Total eligible population
N=2955
Not clinically stable (N=475)
Clinically stable population
N=2480
Creatinine > 300µmol/L (N=6)
No creatinine measures (N=343)
No lung function (N=35)
Study population with lung function and
serum creatinine
N= 2096
Fig. 1. Flow diagram of study participants.
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database, thus increasing confidence in the conclusions that can
be drawn from these data. One particular strength of the studyTable 1
Description of study population of clinically stable adults with cystic fibrosis
who provided annual assessment data in 2008.
Provided baseline
data on serum
creatinine and FEV1
Did not provide
data on serum
creatinine and FEV1
Number 2096 384
Male, (%) 1165 (56) 218 (57)
Age, years (%)
18–19 299 [14] 60 [16]
20–29 1051 [50] 181 [47]
30–39 469 [22] 88 [23]
40+ 277 [13] 55 [14]
Age, years, (sd) 28.9 (9.0) 29.4 (10.0)
FEV1, L, (sd) 2.36 (1.03) 2.42 (1.00)
N=323
Predicted FEV1, %, (sd) 65.1 (24.2)
N=2079
67.8 (25.2)
N=283
FVC, L, (sd) 3.53 (1.2) 3.54 (1.17)
N=323
Predicted FVC, %, (sd) 82.7 (21.4)
N=2079
84.3 (22.3)
N=283
BMI,kg/m2 (%)
b20 503 [24] 85 [26]
20 to 24.9 1177 (57) 182 (56)
≥25 390 [19]
N=2070
60 [18]
N=327
Height, m, (sd) 1.68 (0.1)
N=2079
1.68 (0.1)
N=335
Serum creatinine, μmol/L, (sd) 77.2 (22.0)
N=2096
71.5 (23.9)
N=35
FEV1=Forced Expiratory Volume in one second.
FVC=Forced Vital Capacity.
BMI=Body Mass Index.was the ability to identify and exclude patients that were not
considered to be clinically stable by the specialist clinic, min-
imising the risk of confounding by acute exacerbations that may
reduce both lung and renal function. Another strength of our data
was the ability to investigate the associations between obesity and
lung function after adjustment for a measure of lean muscle mass,
thus permitting calibration of the relative importance of these two
measures on lung function for the first time. Finally, the linear
nature of the associations observed and the consistency of our
observations after sensitivity analyses using different cut off
points for the ceiling level of serum creatinine, increases our
confidence that these associations are not driven by extreme data
points.
Our data have a number of limitations that require consider-
ation. It is possible that some individuals may have had a
subclinical infection at the time of their annual review that was
not noted by the clinician involved. However, this would beFig. 2. Association between lung function and body mass index.
Table 2
A multivariate analysis of the association between measures of body habitus
and lung function in adults with cystic fibrosis.
Number of
individuals
FEV1 (ml) FVC (ml)
Creatinine (per sex
specific sd change)
Male 1153 +171
(+116 to +227)
+99
(+41 to +157)
Female 917
(pinteraction
=0.03)
+90
(+46 to +133)
+64
(+19 to +110)
Body mass index (kg/m2)
Male
b20 228 −642
(−784 to −500)
−663
(−810 to −515)
20–24.9 670 0 0
≥25 255 +364
(+227 to +501)
+272
(+130 to +415)
Female
b20 275 −468
(−564 to −372)
−507
(−609 to −405)
20–24.9 507 0 0
≥25 135
(pinteraction
=0.09)
+237
(+113 to +360)
+192
(+61 to +323)
Mutually adjusted model includes for sex, age (categorical variable), body mass
index (categorical variable) and height.
sd=standard deviation.
FEV1=Forced Expiratory Volume in one second.
FVC=Forced Vital Capacity.
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than generate spuriously positive associations. In addition, the
exclusion of patients who were not stable at the time of annual
review suggest that our data cannot be generalised to this group of
patients who may have more progressive disease. Also, we are
unable to exclude the possibility that the associations that we are
observing may be a consequence of confounding by other factors
such as inflammation in early life [27]. Finally, the study
population may contain some individuals who have received a
lung transplantation and are now classified as clinically stable,
although the absolute numbers of individuals compared to the
total population will be small (approximately 40/year [28]) and
unlikely to influence the associations observed.
Our use of serum creatinine as an epidemiological marker of
lean muscle mass also requires critical consideration. Clinicians
have been aware for years that muscle mass is positively
associated with serum creatinine, and that caution is required
when estimating renal function in bodybuilders [29,30] or the
elderly [31], where extremes of muscle bulk may make the
serum creatinine unreliable. A consequence of muscle turnover,
creatinine is released at a consistent rate from skeletal muscle
[32]. Data from a study of 24 men who provided paired
measures of plasma creatinine and 24-hour urinary creatinine
excretion [21], a validated measure of lean muscle mass [33],
demonstrated that total plasma creatinine correlated strongly
with urinary creatinine excretion with a correlation coefficient
of 0.82, suggesting that blood creatinine may be used as anindirect measure of muscle mass. Similarly, a more recent study
in healthy adults presented a strong correlation (r=0.73) between
serum creatinine and fat-free mass [24], and another study of
children with leukaemia demonstrated a correlation co-efficient
of 0.52 for serum creatinine concentration with lean body mass
[23]. Animal studies in dogs suggest that plasma creatinine can
predict muscle mass to within 3.9% of observed muscle mass
[21]. As a consequence of these studies, we have recently used
serum creatinine as an epidemiological measure of lean muscle
mass in cystic fibrosis demonstrating lower mortality for
individuals with higher levels of serum creatinine [25] while
other researchers have used it for similar purposes in a study of
1017 individuals with diabetes [22]. We consider it likely that
there will be a large amount of measurement error in the use
of serum creatinine as a biomarker for muscle mass in large
populations, which may result in a reduction in the size of
association seen compared to the true association.
The use of creatinine as a biomarker of lean muscle mass in
adults with cystic fibrosis in our dataset is relatively novel and
is susceptible to the many endogenous and exogenous in-
fluences intrinsic to CF that may confound the associations
observed. These will include renal impairment in patients with
CF [34], often but not always as a consequence of exposure to
multiple courses of aminoglycoside antibiotics or the presence
of a diagnosis of diabetes. However, we would anticipate that
those with impaired renal function would have more severe
disease, and as a consequence expect that higher creatinine
would be inversely associated with lung function, when in fact
the converse is observed in our data. In addition, the associations
were consistent across the sensitivity analyses that eliminated
higher values of serum creatinine above 100 μmol/L, and so we
are confident that these associations are not a consequence of
high outlying values. However, it is possible that our observation
that serum creatinine is positively associated with lung function
may be attenuated by some patients with more severe disease
having lower lung function and higher levels of creatinine. If this
is the case, then the true association between serum creatinine and
lung function would be higher than indicated by our data. Future
studies of these associations would benefit from using measures
of serum cystatin C in addition to serum creatinine, to adjust for
mild levels of renal impairment.
There have been a number of small studies in both children
and adults that have used DEXA scans to assess muscle bulk in
individuals with cystic fibrosis. These have generally reported
that patients with cystic fibrosis have less lean body mass than
healthy controls [16,18,20,35–40]. In addition, it has been
demonstrated that fat free mass is positively associated with
lung function [9,17,18,20,38,41,42]. However, to our knowl-
edge, this is the first study to demonstrate that reduced lean
muscle mass as measured by serum creatinine is positively
associated with lung function in a nationally representative
population of adults with cystic fibrosis. This association is
qualitatively similar to that reported by ourselves in a population-
based study that used 24-hour urinary creatinine excretion to
quantify lean muscle mass [43]. However, the size of association
differed between the two populations, with a one standard
deviation increase in serum creatinine in our data from individuals
288 D.L. Forrester et al. / Journal of Cystic Fibrosis 12 (2013) 284–289with cystic fibrosis being associated with an increase in FEV1 of
90 to 171 ml, while a one standard deviation increment of
24-hour urinary excretion was associated with a 45 ml increase in
FEV1. This may be a consequence of the measurement error in
the two different methods of quantifying lean muscle mass,
or alternatively may reflect a difference between the two
populations.
As our data are cross-sectional, we are unable to draw any
conclusions regarding causality and can only speculate as to
possible explanations for this association. Firstly, the observed
associations may be a consequence of damaged lungs reducing
exercise capacity and hence resulting in lower muscle bulk
[24], and this is consistent with the observation that skeletal
muscle strength is reduced during an acute pulmonary exacerba-
tion of CF [44]. Secondly, capacity to exercise, itself a predictor
of survival [45] may modify skeletal muscle mass and also may
impact on lung function by reducing respiratory muscle strength
[19,46]. Finally, the association may be confounded by disease
severity, probably via a combination of malabsorption, pul-
monary infections and systemic inflammation [47,48]. As the
positive associations between both BMI and fat free mass with
lung function are seen in children with an average age of
13 years, the processes that underpin this association may be
present from an early life onwards [9].
Although the association between body mass index or similar
epidemiological anthropometric measures and lung function in
cystic fibrosis has been previously reported [6–9,15,20], the
previous observational epidemiological studies of these associ-
ations did not adjust for potential confounding factors such lean
muscle mass. The positive association between body mass index
and lung function in cystic fibrosis is the opposite of that
observed in healthy populations of adults where body mass index
is inversely associated with lung function [49], and explaining
this paradox may increase wider understanding on relationships
between BMI and lung function generally. Our data are con-
sistent with national data from the CF Foundation Registry which
also suggests a positive association between FEV1 and BMI, that
continues to increase beyond the value of 25 m2/kg [13].
Although BMI is a validated measure of adiposity in adults
[50], it has not been validated in CF and hence may be a
composite of other anthropometric components in this disease.
Untangling these potentially complex relations between
body habitus and lung function will require longitudinal study
designs, including observational studies and randomised con-
trolled trials, ideally over an extended period of time. Such
interventions should consider the impact of optimising lean
muscle mass on physiological and quality of life related outcome
measures and could include exercise based training programmes
[51] and dietary supplementation with amino acids [52]. CF
multidisciplinary teams typically include a specialist physiother-
apist and specialist dietician and are ideally placed to provide a
platform for physical and nutritional interventions based upon
emerging supportive evidence.
In conclusion we demonstrate that serum creatinine, a
biomarker for lower lean muscle mass, and BMI are independently
positively associated with lung function in CF. Randomised
controlled studies are required to identify interventions thattarget these outcome measures with a view to improving clinical
outcomes in cystic fibrosis.
Support statement
Doug Forrester is funded by Wellcome Trust Fellowship
WT088614MA.
Role of the funding source
The funding source had no role in study design, data
analysis or decision to submit the manuscript for publication.
Conﬂict of interest statement
The authors have no conflict of interest that could bias the
data presented.
Acknowledgements
We thank the UK Cystic Fibrosis Trust and the specialist
cystic fibrosis teams who contributed data.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.08.008.
References
[1] Forrester D, Knox A, Smyth A, Dewar J, Fogarty A. Are different
measures of body habitus associated with lung function in individuals with
cystic fibrosis? A cross-sectional study. Pediatr Pulmonol 2011;46:S34.
[2] VandenBranden S, McMullen A, Schechter M, Pasta D, Michaelis R,
Konstan M, et al. Lung function decline from adolesence to young
adulthood in cystic fibrosis. Pediatr Pulmonol 2012;47:135-43.
[3] O'Sullivan B, Freedman S. Cystic fibrosis. Lancet 2009;373:1891-904.
[4] Sharma R, Florea V, Bolger A, Doehner W, Florea N, Coates A, et al.
Wasting as an independent predictor of mortaluty in patients with cystic
fibrosis. Thorax 2001;56:746-50.
[5] Kerem E, Reisman J, Corey M, Canny G, Levison H. Prediction of
mortality in patients with cystic fibrosis. N Eng J Med 1992;326:1187-91.
[6] Jarad N, Higgs S, Jeffcote S, Giles K. Factors associated with reduced
FEV1 in adult patients with cystic fibrosis in a relatively affluent area.
Chron Respir Dis 2005;2:133-7.
[7] Chaves C, de Britto J, de Oliveira C, Gomes M, da Cunha A. Assaciacao
entre medidas do estado nutricional e a funcao pulmonar de criancas e
adolescentes com fibrose cistica. J Bras Pneumol 2009;35:409-14.
[8] Bell S, Bowerman A, Davies C, Campbell I, Shale D, Elborn S. Nutrition
in adults with cystic fibrosis. Clin Nutr 1998;17:211-5.
[9] Pedreira C, Robert R, Dalton V, Oliver M, Carlin J, Robinson P, et al.
Association of body composition and lung function in children with cystic
fibrosis. Pediatr Pulmonol 2005;39.
[10] dos Santos Simon M, Drehmer M, Silva F, Hoffman A, Ricachinewsky C,
Procianoy E, et al. Association of nutritional status, plasma, albumin
levels and pulmonary function in cystic fibrosis. Nutr Hosp 2011;26:
1322-7.
[11] Gozdzik J, Cofta S, Piorunek T, Batura-Gabryel H, Kosicki J. Relationship
between nutritional status and pulmonary function in adult cystic fibrosis
patients. J Physiol Pharm 2008;59:253-60.
[12] Stallings V, Stark L, Robinson K, Ferachak A, Quinton H. Evidence-based
practice recommendations for nutrition-related management of children and
289D.L. Forrester et al. / Journal of Cystic Fibrosis 12 (2013) 284–289adults with cystic fibrosis and oancreatic insufficiency: results of a systematic
review. J Am Diet Assoc 2008;108:832-9.
[13] Matel J. Nutritional management of cystic fibrosis. J Parenteral Enteral
Nutrition 2012;36:60S-7S.
[14] Milla C. Nutrition and lung disease in cystic fibrosis. Clin Chest Med
2007;28:319-30.
[15] Navarro J, Rainisio M, Harms H, Hodson M, Koch C, Mastella G, et al.
Factors associated with poor pulmonary function: cross-sectional analysis
of data from the ERCF. Eur Resp J 2001;18:298-305.
[16] Ionescu A, Nixon L, Evans W, Stone M, Lewis-Jenkins V, Chatham K,
et al. Bone density, body composition, and inflammatory status in cystic
fibrosis. Am J Respir Crit Care Med 2000;162:789-94.
[17] King S, Nyulasi I, Strauss B, Kotsimbos T, Bailey M, Wilson J. Fat-free
mass depletion in cystic fibrosis: associated with lung disease severity but
poorly detected by body mass index. Nutrition 2010;26:753-9.
[18] Bolton C, Ionescu A, Evans W, Pettitt R, Shale D. Altered tissue
distribution in adults with cystic fibrosis. Thorax 2003;58:885-9.
[19] Ionescu A, Chatham K, Davies D, Nixon L, Enright S, Shale D.
Inspiratory muscle function and body composition in cystic fibrosis. Am J
Respir Crit Care Med 1998;158:1271-6.
[20] Ionescu A, Evans W, Pettitt R, Nixon L, Stone M, Shale D. Hidden
depletion of fat-free mass and bone mineral density in adults with cystic
fibrosis. Chest 2003;124:2220-8.
[21] Schutte J, Longhurst J, Gaffney A, Bastian B, Blomquist C. Total plasma
creatinine: an accurate measure of total striated muscle mass. J Appl
Physiol 1981;51:762-6.
[22] Hjelmesaeth J, Roislien J, Nordstrand N, Hofso D, Hager H, Hartmann A.
Low serum creatinine is associated with type 2 diabetes in mordily obese
women and men: a cross-sectional study. BMC Endocrine Disorders
2010;10:6.
[23] Morrison J, Nayiager T, Webber C, Sala A, Barr R. Creatinine as a
measure of lean body mass during treatment of acute lyphoblastic
leukaemia in childhood. J Pediatr Hematol Oncol 2011;33:e13-6.
[24] Baxmann A, Ahmed M, Marques N, Menon V, Pereira A, Kirsztajn G,
et al. Influence of muscle mass and physical activity on serum and urinary
creatinine and serum cystatin C. Clin J Am Soc Nephrol 2008;3:348-54.
[25] Fogarty AW, Britton J, Clayton A, Smyth A. Are measures of body
habitus associated with mortality in cystic fibrosis? CHEST in press,
http://dx.doi.org/10.1378/chest.11–2124.
[26] Mehta G, Sims EJ, Culross F, McCormick JD, Mehta A. Potential benefits
of the UK Cystic Fibrosis Database. J R Soc Med 2004;97(Suppl. 44):
60-71.
[27] Ranganathan S, Parsons F, Gangell C, Brennan S, Stick S, Sly P.
Evolutaion of pulmonary inflammation and nutritional status in infants
and young children with cystic fibrosis. Thorax 2011;66:408-13.
[28] Personal Communication: National Health Service Blood and Transplant
(20/7/2012).
[29] Stevens L, Coresh J, Greene T, Levey A. Medical progress: assessing
kidney function—measured and estimated glomerular filtration rate. New
Eng J Med 2006;354:2473-83.
[30] Kim H, Lee S, Choue R. Metabolic responses to high protein diet in
Koprean elite bodybuilders with high-intensity resistance exercise. J Int
Soc Sports Nutr 2011;8:10.
[31] Cattell W, Baker L, Greenwood R. Renal Disease. In: Kumar P, Clark M,
editors. Clinical Medicine. London: Bailliere Tindall; 1990. p. 488.
[32] Heymsfield S, Gallagher D, Visser M, Nunez C, Wang Z-M. Measure of
skeletal muscle: laboratory and epidemiological methods. J Gerontology
Series A 1995;50A:23-9.
[33] Lukaski H. Sarcopenia: assessment of muscle mass. J Nutr 1997;127:
994S-7S.[34] Bertenshaw C, Watson A, Lewis S, Smyth A. Survey of acute renal failure
in patients with cystic fibrosis in the UK. Thorax 2007;62:541-5.
[35] Shepherd R, Thomas B, Bennett D, Cooksely W, Ward L. Changes in
body composition and muscle protein degradation during nutritional
supplementation in nutritionally growth-retarded children with cystic
fibrosis. J Ped Gastro Nutr 1983;2:439-46.
[36] Miller M, Ward L, Thomas B, Cooksley W, Shepherd R. Altered body
composition and muscle protein degradation in nutritionally growth-retarded
children with cystic fibrosis. Am J Clin Nutr 1982;36:492-9.
[37] Newby M, Keim N, Brown D. Body composition of adult cystic fibrosis
patients and control subjects as determined by densitometry, bioelectrical
impedance, total-body electrical conductivity, skinfold measurements, and
deuterium oxide dilution. Am J Clin Nutr 1990;52:209-13.
[38] Rochat T, Slosman D, Pichard C, Belli D. Body composition analysis by
dual-energy X-ray absorptiometry in adults with cystic fibrosis. Chest
1994;106:800-5.
[39] Henderson R, Madsen C. Bone mineral content and body composition in
children and young adults with cystic fibrosis. Pediatr Pulmonol 1999;27:
80-4.
[40] Pinet C, Cassart M, Scillia P, Lamotte M, Knoop C, Casimir G, et al.
Function and bulk of respiratory and limb muscles in patients with cystic
fibrosis. Am J Respir Crit Care Med 2003;168:989-94.
[41] Ionescu A, Nixon L, Luzio S, Lewis-Jenkins V, Evans W, Stone M, et al.
Pulmonary function, body composition, and protein catabolism in adults
with cystic fibrosis. Am J Respir Crit Care Med 2002;165:495-500.
[42] Williams J, Wells J, Benden C, Jaffe A, Suri R, Wilson C, et al. Body
composition assessed by the 4-component model and association with
lung function in 6–12 year old children with cystic fibrosis. Am J Clin
Nutr 2010;92:1332-43.
[43] Fogarty A, Lewis S, McKeever T, Britton J. The association of two
different measures of body habitus with lung function: a population-based
study. Respir Med 2011;105:1896-901.
[44] Wieboldt J, Atallah L, Kelly J, Shrikrishna D, Gyi K, Lo B, et al. Effect of
acute exacerbations on skeletal muscle strength and physical activity in
cystic fibrosis. J Cystic Fibrosis 2012;11:209-15.
[45] Moorcroft A, Dodd M, Webb A. Exercise testing and prognosis in adult
cystic fibrosis. Thorax 1997;52:291-3.
[46] Enright S, Chatham K, Ionescu A, Unnithan V, Shale D. The influence of
body composition on repiratory muscle, lung function and diaphragm
thickness in adults with cystic fibrosis. J Cystic Fibrosis 2007;6:384-90.
[47] Levy H, Kalish L, Huntingdon I, Weller N, Gerard C, Silverman E, et al.
Inflammatory markers of lung disease in adult patients with cystic fibrosis.
Pediatr Pulmonol 2007;42:256-62.
[48] Downey D, Martin S, Dempster M, Moore J, Keogan M, Starcher B, et al.
The relationship of clinical and inflammatory markers to outcome in stable
patients with cystic fibrosis. Pediatr Pulmonol 2007;42:216-20.
[49] McClean K, Kee F, Young I, Elborn J. Obesity and the lung: 1 —
Epidemiology. Thorax 2008;63:649-54.
[50] Sun Q, van Dam R, Spiegelman D, Heymsfield S, Willett W, Hu F.
Comparison of dual-energy x-ray absorptiometric and anthropometric
measures of adiposity in relation to adiposity-related biologic factors. Am
J Epidemiol 2010;172:1442-54.
[51] Selvadurai H, Blimkie C, Meyers N, Mellis C, Cooper P, Van Asperen P.
Randomised controlled study of in-hospital exercise training in children
with cystic fibrosis. Pediatr Pulmonol 2002;33:194-200.
[52] Poustie V, Watling R, Smyth R. Oral protein-energy supplements for
children with chronic disease: systematic review. Proc Nutr Soc 2003;62:
801-6.
